ESPR Q3 2024 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$577M

Q3 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$52M+52.0% YoY

Gross Profit

$34M66.5% margin

Operating Income

-$16M-31.0% margin

Net Income

-$30M-57.2% margin

EPS (Diluted)

$-0.15

QoQ Revenue Growth

-30.1%

Cash Flow

Operating Cash Flow

-$35M

Free Cash Flow

-$35M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$314M

Total Liabilities

$684M

Stockholders' Equity

-$370M

Cash & Equivalents

$145M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$52M	$34M	+52.0%
Gross Profit	$34M	$21M	+66.8%
Operating Income	-$16M	-$28M	+41.8%
Net Income	-$30M	-$41M	+28.4%

Revenue Segments

Product

$31M60%

Collaboration Revenue

$21M40%